Zentalis Pharmaceuticals (NASDAQ:ZNTL) Issues Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) announced its earnings results on Thursday. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08), FiscalAI reports.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $2.10 on Friday. Zentalis Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $3.95. The firm’s 50-day moving average is $2.57 and its 200 day moving average is $1.94. The company has a market capitalization of $151.73 million, a PE ratio of -1.11 and a beta of 1.71.

Insider Activity

In other news, insider Vincent Vultaggio sold 29,951 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total transaction of $72,780.93. Following the completion of the sale, the insider owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. The trade was a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Group Walters acquired 6,459,973 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the purchase, the insider owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders sold 46,617 shares of company stock valued at $113,417. 1.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter worth $41,000. Qube Research & Technologies Ltd bought a new position in Zentalis Pharmaceuticals during the 2nd quarter worth about $37,000. Algert Global LLC purchased a new position in Zentalis Pharmaceuticals during the 3rd quarter valued at about $73,000. Corient Private Wealth LLC purchased a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at about $83,000. Finally, Opal Capital LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 4th quarter valued at about $98,000.

Wall Street Analysts Forecast Growth

Several research firms have commented on ZNTL. Guggenheim reaffirmed a “buy” rating and set a $6.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Wells Fargo & Company began coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.17.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.